
Please try another search
Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252 (POZ-apomorphine), a POZ conjugate for the treatment of advanced Parkinson’s disease that is in preclinical stage development; and POZ-lipids, a non-immunogenic alternative to the PEG-lipids in the lipid nanoparticles. The company also develops SER 214 a POZ conjugate of rotigotine for the treatment of early Parkinson’s and Restless Leg Syndrome, which has completed phase 1a clinical trial. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. Serina Therapeutics, Inc. was founded in 2006 and is based in Huntsville, Alabama.
Name | Age | Since | Title |
---|---|---|---|
Richard Marshall | 57 | 2024 | Director |
J. Milton Harris | 84 | 2024 | Co-Founder, Director Emeritus & Chair of Scientific Advisory Board |
Balkrishan Gill | 60 | 2024 | Executive Chairman |
Karen J. Wilson | 62 | 2025 | Independent Director |
Steven A. Ledger | 66 | 2024 | CEO & Director |
Jay R. Venkatesan | 53 | 2025 | Independent Director |
Gregory H. Bailey | 69 | 2024 | Independent Director |
William K. Schmidt | 74 | - | Member of Scientific Advisory Board |
Stephen K. Brannan | 69 | 2025 | Director |
Gaurav Sahay | - | - | Member of Scientific Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review